Skip to content
Healing & RepairGrade D — Weak, conflicting or negative3 primary sources

Wolverine Stack

Also known as Wolverine blend · BPC-157 / TB-500 stack

The BPC-157 plus TB-500 combination, marketed for injury recovery. Neither compound has completed a human efficacy trial, and the combination has never been studied.

Community dosage infoView dosing research

Overview

The pairing is marketed on the idea that BPC-157 and TB-500 work on repair through different routes — one on angiogenesis and growth factor signalling, the other on cell migration through actin — so together they should cover more ground. It is a plausible story. It is also entirely untested: neither compound has a completed human efficacy trial, and no study has ever examined them together.

Research areas

Tendon and ligament repairSoft tissue injuryMusculoskeletal recovery

Community-specified data

Community dosage information

Unverified
Community protocol

BTMK Blend (BPC 10mg|TB4 2.5mg|MGF 1mg|KPV 1mg)

Third-party
01Reconstitution solution
1 mL
02Dose
1.45 mg
03Syringe units
10 units
04Frequency
7x/week
05Cycle length
90 days
06Bacteriostatic water
1 mL
07Bottle size
14.5 mg
08Bottles needed
9

Source note: 10 units yields 1mg BPC / 250mcg TB4 / 100mcg MGF / 100mcg KPV

Track this schedule
Community protocol

TRI-HEAL 45mg (TB500 25mg|BPC-157 10mg|KPV 10mg)

Third-party
01Reconstitution solution
2 mL
02Dose
2.25 mg
03Syringe units
10 units
04Frequency
7x/week
05Cycle length
90 days
06Bacteriostatic water
2 mL
07Bottle size
45 mg
08Bottles needed
5

Source note: Yields 1.25mg TB4 / 0.5mg BPC / 0.5mg KPV

Track this schedule

Not medical guidance. These third-party figures have not been independently verified, clinically reviewed, or endorsed by DB Peptide. They may be inaccurate or unsafe and should not replace product labelling or advice from a qualified clinician.

Dosing reported in the literature

Every protocol below is reproduced from a published study or approved labelling, with its source named. These are records of what was studied — not recommendations, and not a suggestion that any of them is appropriate for any person.

Protocol as reportedSource
Vendor-published stack protocols, typically a loading phase followed by maintenance over several weeksNot derived from any published study.Supplier marketing material

Trial status

No trials of the combination. Component evidence is preclinical or, for TB-500, belongs to the parent protein.

Reported safety signals

  • No safety data exists for the combination.
  • Both components are pro-angiogenic, which compounds the theoretical oncologic concern noted on each individual profile.
  • Blending removes any ability to attribute an effect or an adverse event to one compound.
  • Both are prohibited in competitive sport at all times.

Common questions

Is there any human trial of BPC-157?

There have been early-phase studies in inflammatory bowel disease, but no completed and published randomised efficacy trial for injury or tendon healing in humans. Effectively all the healing evidence you will encounter is from rodents.

Primary sources

3 citations
  1. 01

    Brain-gut axis and pentadecapeptide BPC 157: theoretical and practical implications

    Current Neuropharmacology2016

  2. 02

    Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease

    Current Pharmaceutical Design2011

  3. 03

    Thymosin β4: a multi-functional regenerative peptide

    Expert Opinion on Biological Therapy2012

Medical disclaimer

This page is for informational and research purposes only. Nothing here constitutes medical advice. The compounds discussed are research chemicals. Consult a qualified clinician before starting any protocol.

How this profile was built →